Premium
Immunohistochemical study of receptor activator of nuclear factor kappa‐B ligand (RANK‐L) in human osteolytic bone tumors
Author(s) -
Good Christopher R.,
O'Keefe Regis J.,
Puzas J. Edward,
Schwarz Edward M.,
Rosier Randy N.
Publication year - 2002
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.10067
Subject(s) - medicine , immunohistochemistry , kappa , activator (genetics) , rank ligand , rankl , receptor , pathology , philosophy , linguistics
Abstract Background and Objectives Osteolytic bone tumors produce intercellular signaling proteins that regulate bone remodeling by altering the rates of osteoclast and osteoblast differentiation and activity. This report examines osteolytic bone tumor expression of receptor activator of nuclear factor B‐ligand (RANK‐L), a cytokine that is arguably the most critical regulator of osteoclast differentiation and activation. Methods This prospective immunohistochemical study examined RANK‐L expression in frozen tissues from sixteen surgical specimens of patients who underwent surgery for the treatment of osteolytic bone tumors between 1999 and 2000. Results RANK‐L was positive in 13 of the 16 cases. Primary benign bone tumors, primary malignant bone tumors, and metastasis to bone were positive for RANK‐L. Conclusions The cells in some, but not all, osteolytic tumors produce the cytokine RANK‐L. Further study is necessary to determine in which specific tumors RANK‐L is the cytokine responsible for increased osteoclastic activity, and to develop possible therapeutic use of RANK‐L antagonists such as osteoprotegerin (OPG). J. Surg. Oncol. 2002;79:174–179. © 2002 Wiley–Liss, Inc.